On the first day of construction, Pinsheng Medical launched the first shot in the field of clinical mass spectrometry

On the first day of construction in the Renyin Year of the lunar calendar, Pinsheng Medical (formerly known as "Pinsheng Medical") launched the first shot in the field of clinical mass spectrometry

On February 7, Pinsheng Medical officially announced that it changed its name to "Pinsheng Medical" , the English abbreviation is "Qlife", and the company's full name is "Jiangsu Pinsheng Medical Technology Group Co.

Since its establishment in 2016, Pinsheng Medical has developed rapidly.

Why did Pinsheng Medical choose to make a drastic brand upgrade when the product system is completed, the capital market is generally optimistic, and the business is in a stage of rapid growth? What's the thinking behind it? What major moves will the company make in the future in terms of development strategy and business layout? Recently, Arterial Network conducted an exclusive interview with Dr.

Choose a different path than the US market

Be the first to clarify the IVD business model

In 2013, Dr.

After returning to China, Dr.

"China's clinical mass spectrometry market started late, and imitating the ICL (third-party medical testing) model in the United States was the main practice in the early stage of the industry

Therefore, after the establishment of Pinsheng Medical in 2016, Dr.

The superiority of this business model was quickly verified in China, and it has been widely recognized in the field of clinical mass spectrometry.

With the forward-looking layout of the clinical mass spectrometry IVD business model, Pinsheng Medical has fully enjoyed the dividends of the rapid growth of the clinical mass spectrometry market

If it is said that the "IVD-based, ICL-assisted" model has made Pinsheng Medical firmly in the leading position in the industry, and it is also the core factor for the qualitative change of China's clinical mass spectrometry rapid jump from a toddler to a Chaoyang track, then the clinical mass spectrometry industry has ushered in Where is the next qualitative change in the outbreak? Dr.

Be the first batch of omics researchers

Promoting qualitative change in multi-omics and clinical mass spectrometry

2010-2020 is the era of genomics.

"The occurrence and development of diseases are complex, and a single omics cannot solve all problems.

Consistent with Dr.

Clinical mass spectrometry is the core detection technology of proteomics and metabolomics.

Dr.

qULTRA is a leading clinical proteomics and metabolomics research platform, which solves the bottleneck problems of poor stability, low throughput and high cost of traditional omics research, realizes targeted and non-targeted clinical omics research, and completes the transition from novel omics research.
From the discovery of biomarkers, to the verification of innovative clinical diagnostic technologies, to the closed-loop transformation of clinical diagnostic products, high-precision omics research technologies can be transformed into technologies that are truly suitable for large-scale and large-scale clinical testing applications
.

"In a nutshell, the ability of omics research determines the ability of clinical mass spectrometry companies to continue to develop innovative clinical diagnostic applications.
Only companies that can collect accurate omics data with high efficiency and high quality, and have the ability to mine, analyze, and continuously develop innovative diagnostic application products can stand out
.
"

"Conventional projects such as vitamins and drug concentrations already have many competitors, and innovative projects are a new growth point for the company
.
Relying on omics research capabilities, Pinsheng Medical synchronously deploys metabolome and proteome, in maternal and child, tumor, endocrine/cardiovascular, neurological , metabolism and other fields have reserved a number of potential explosive special inspection products
.
"

In 2021, Dr.
Cheng Xiaoliang noticed that the multi-omics research that had been closely followed before has shown a faint trend of outbreak
.
The name was changed to "Pinsheng Medical" in early 2022, precisely to fully embrace the era of bio-omics.
The difference between "medicine" and "medical" means that the company will fully promote multi-omics research and develop more innovative applications of mass spectrometry products, extend to deeper medical scenarios, and serve more types of customers
.

  Omic era  

Clinical Mass Spectrometry Will Empower a Wider Range of Precision Medicine Scenarios

Today, although China's clinical mass spectrometry is in its infancy, it has become a golden track that is closely followed by people in the precision medicine industry
.
From 2016 to 2021, Dr.
Cheng Xiaoliang felt the transformation from quantity to quality in China's clinical mass spectrometry industry
.

In terms of technology popularity, whether it is self-built mass spectrometry detection platform or outsourced sample detection, the popularity of clinical mass spectrometry detection projects in terminal hospitals is getting higher and higher.
The willingness to popularize technology is strong
.

In terms of application expansion, the clinical application of mass spectrometry has rapidly expanded from newborn screening and vitamin detection to hormones, amino acids, fatty acids, blood drug concentration monitoring and other fields.
There are hundreds of detection items.
Innovative fields such as women and children have also begun to show application potential
.

On the server side, there are more and more third-party medical laboratories conducting clinical mass spectrometry testing, and the service level has been comprehensively improved in terms of the number of testing items, reporting time, and testing quality
.

" Pinsheng Medical has caught up with the good time of the rise of clinical mass spectrometry in China, and stepped on the development drum of the times
.
The clinical mass spectrometry detection project is mature, the supporting industry chain is perfect, the clinical promotion and popularization, and the era of omics is coming, which is bringing greater opportunities.

.
Pinsheng Medical is ready to meet a wider range of precision diagnosis and treatment scenarios and build a new ecology of precision medicine based on omics technology
.
"

Dr.
Cheng Xiaoliang predicted: " Multi-omics research will usher in an explosion within three years
.
The various links in the omics technology, such as sample pretreatment, mass spectrometry analysis, data processing, and bioinformatics analysis, have been opened up, forming a platform-based technology for Standardized and large-scale clinical omics research provides powerful tools, which can provide more support for clinical research in proteomics and metabolomics, and also open up clinical testing applications based on omics technology
.
"

In the future, under the multi-omics trend, clinical mass spectrometry technology is expected to surpass the brilliance of gene sequencing technology
.
Next, the detection and application innovation ability with the omics research ability as the core will be the key element for enterprises to build core barriers
.
It can be seen that Pinsheng Medical's brand VI upgrade is obviously "prepared".
In the era of bio- omics, the integrated layout covering omics research, equipment, reagents, and testing will be the way for Pinsheng Medical to develop clinical and drug products.
development, as well as the ace of the international market
.

" In the next 3-5 years, Pinsheng Medical will continue to put into practice the construction of a benign industrial ecology, including inviting more industrial partners to join the Pinsheng Medical ecosystem, opening up more technology, market, and marketing resources, and strengthening industry-university-research collaboration.
Cultivate mass spectrometry talents, so that mass spectrometry equipment, reagents, detection, omics research, medical institutions, pharmaceutical companies, scientific research institutes and other ecological members support each other, and improve the efficiency of precision medical ecological operation
.
" Dr.
Cheng Xiaoliang said
.